默沙东今天宣布,全球首个针对肺动脉高压核心病理机制的全人源生物制剂欣瑞来(注射用索特西普)在中国境内上市,用于治疗世界卫生组织功能分级(WHO FC)Ⅱ-Ⅲ级的肺动脉高压(PAH,WHO第1组)成年患者,填补了针对PAH疾病根源的治疗空白。 默沙东全球高级副总裁、默沙东中国总裁唐凯宇表示:“肺动脉高压作为一种相对复杂的心血管疾病,严重影响患者的日常运动、生活能力甚至危及生命,新诊断患者的5年...
Source Link默沙东今天宣布,全球首个针对肺动脉高压核心病理机制的全人源生物制剂欣瑞来(注射用索特西普)在中国境内上市,用于治疗世界卫生组织功能分级(WHO FC)Ⅱ-Ⅲ级的肺动脉高压(PAH,WHO第1组)成年患者,填补了针对PAH疾病根源的治疗空白。 默沙东全球高级副总裁、默沙东中国总裁唐凯宇表示:“肺动脉高压作为一种相对复杂的心血管疾病,严重影响患者的日常运动、生活能力甚至危及生命,新诊断患者的5年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.